Perinatal EvidenceCompass
Prepopulated workbenchMED-011

Antidepressants — SNRI/dual reuptake

Milnacipran

SNRI; FDA-approved in the US for fibromyalgia, not major depressive disorder; antidepressant use is jurisdiction-specific

Not a categorical safety rating

This record organizes questions; it does not close them.

The clinical fields and position statements are prepopulated from the public-source corpus. They have not completed individual dual extraction, formal appraisal, exact-label reconciliation, or multidisciplinary sign-off. Do not use this page to justify abrupt discontinuation or reflexive switching.

Inventory identity

What this record represents

Canonical generic name
Milnacipran
Entity type
single-ingredient drug
Active component(s)
Milnacipran
Formulation / route / interval
Oral; formulation varies
Attachment entry
Milnacipran
Separate monograph status
No — cross-reference shared molecule monograph
Identity and cross-reference
Not populated in v0.95
Inventory verification confidence
Moderate — molecule-level source; exact product/jurisdiction pending

Decision taxonomy

Five positions kept separate

These are workbench statements for reviewer execution. They are not independently commissioned, patient-specific recommendations.

  1. 01

    Stable continuation

    Workbench statement

    Do not withhold or discontinue solely because of pregnancy or lactation. For this record, assess indication, prior response, relapse severity, dose/formulation, alternatives, exposure timing, and mapped evidence; individual commissioned adjudication remains pending.

  2. 02

    New initiation in pregnancy

    Workbench statement

    For a new start, prefer an effective option with the strongest diagnosis-specific efficacy and reproductive evidence when clinically suitable. This record has not received an individual, independently verified initiation ranking.

  3. 03

    Switch before conception

    Workbench statement

    Before conception, consider a switch only when expected benefit exceeds relapse, withdrawal, failed-switch, and dual-exposure risks. Build and monitor the plan before pregnancy when feasible; no universal switch direction is assigned here.

  4. 04

    Unplanned exposure

    Workbench statement

    After unplanned exposure, confirm product, route, dose, timing, indication, co-exposures, and symptoms; do not advise abrupt cessation. Use the mapped evidence and current label to decide whether any targeted fetal assessment is indicated.

  5. 05

    Delivery, postpartum & lactation

    Workbench statement

    Create separate delivery, postpartum-dose, neonatal-observation, and lactation plans. Do not infer breastfeeding suitability from pregnancy evidence or routinely taper before delivery without drug-specific support.

Linked evidence

8 mapped claim summaries

Mapping can include class-wide, framework, formulation, regulatory, or evidence-gap claims. A linked claim is not necessarily a drug-specific causal estimate.

A-001Provisional public source

ACOG recommends against withholding or discontinuing a psychiatric medication solely because of pregnancy or lactation.

Public-source certainty descriptor
guideline recommendation; not a formal GRADE rating in this module
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
preconception through lactation
Comparator
continuation versus withholding/discontinuation
Effect or numbers carried forward

No reliable quantitative estimate.

Limitations

Requires individualized benefit-risk assessment and does not mean every medicine should continue.

Sources, citation controls, and verification state
PMID
37486661
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending
A-002Provisional public source

ACOG considers SSRIs first-line pharmacotherapy for perinatal depression/anxiety and SNRIs reasonable alternatives; prior response should guide selection, with sertraline or escitalopram reasonable for a medication-naive patient.

Public-source certainty descriptor
guideline recommendation; not a formal GRADE rating in this module
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
pregnancy and postpartum
Comparator
medication choice
Effect or numbers carried forward

No reliable quantitative estimate.

Limitations

Selection still depends on diagnosis, bipolar screening, severity, comorbidity, interactions, past response, and patient preference.

Sources, citation controls, and verification state
PMID
37486661
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending
A-003Provisional public source

In a selected prospective cohort of pregnant patients with recurrent major depression, discontinuation was associated with more relapse than maintenance.

Public-source certainty descriptor
moderate for a high-recurrence population; limited generalizability; not GRADE
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
pregnancy
Comparator
antidepressant discontinuation versus maintenance
Effect or numbers carried forward

Relapse 68% among 65 discontinuers versus 26% among 82 maintainers.

Limitations

Selected cohort enriched for recurrent illness; nonrandomized treatment decision; not applicable to every patient or drug.

Sources, citation controls, and verification state

Linked sources

PMID
16449615
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending
A-009Provisional public source

Antidepressant exposure near delivery was associated with a small postpartum-hemorrhage increase in a Medicaid mood/anxiety cohort; delivery awareness is warranted, not routine discontinuation.

Public-source certainty descriptor
moderate for association; residual confounding; not GRADE
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
near delivery
Comparator
current exposure versus no current antidepressant
Effect or numbers carried forward

PPH 2.8% with no antidepressant, 4.0% with current serotonin reuptake inhibitor, 3.8% with current non-SRI.

Limitations

Claims outcome/exposure; residual severity and obstetric confounding; broad pharmacologic groups.

Sources, citation controls, and verification state

Linked sources

PMID
23965506
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending
A-010Provisional public source

A 2026 systematic review found conventional antidepressant-autism/ADHD associations attenuated or became nonsignificant with illness, familial, genetic, and paternal controls, arguing against a clear causal interpretation.

Public-source certainty descriptor
moderate against a large causal class effect; agent-specific uncertainty; not GRADE
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
prenatal exposure
Comparator
exposed versus unexposed and negative/familial controls
Effect or numbers carried forward

37 studies; 648,626 exposed and 24,967,806 unexposed children; conventional ADHD RR 1.35 (1.24-1.47) and autism RR 1.69 (1.24-2.30), attenuated in stronger control designs.

Limitations

Heterogeneous studies and outcomes; residual confounding; does not prove zero risk or resolve individual drugs.

Sources, citation controls, and verification state

Linked sources

PMID
42134364
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending
A-067Provisional public source

FDA prescription labeling uses narrative Pregnancy and Lactation Labeling Rule sections rather than the former A/B/C/D/X letter categories.

Public-source certainty descriptor
high for US regulatory framework
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
pregnancy and lactation
Comparator
not applicable
Effect or numbers carried forward

No reliable quantitative estimate.

Limitations

Exact labeling and revision date remain product-specific; non-US systems differ.

Sources, citation controls, and verification state

Linked sources

PMID
Not populated in v0.95
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending
A-069Provisional public source

Venlafaxine's active metabolite can be measurable in nursing infants, duloxetine/desvenlafaxine transfer appears modest or low in small studies, and levomilnacipran/milnacipran evidence is sparse.

Public-source certainty descriptor
low-to-moderate by agent; not GRADE
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
lactation
Comparator
between-agent milk and infant exposure
Effect or numbers carried forward

No reliable quantitative estimate.

Limitations

Small samples and limited newborn/long-term outcomes; class analogy is especially weak for levomilnacipran.

Sources, citation controls, and verification state

Linked sources

PMID
Not populated in v0.95
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending
A-070Provisional public source

Routine pre-delivery taper of an effective antidepressant to prevent neonatal adaptation is not recommended; it may precipitate relapse and does not eliminate exposure.

Public-source certainty descriptor
guideline-consistent position; not GRADE
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
late pregnancy and delivery
Comparator
continuation versus routine taper
Effect or numbers carried forward

No reliable quantitative estimate.

Limitations

Direct randomized taper evidence is limited; individual toxicity or patient preference can still justify a supervised change.

Sources, citation controls, and verification state
PMID
37486661
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending